Myriad Genetic “announced the appointment of George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology, effective March 18, 2024. Dr. Daneker brings more than 30 years of oncology and precision medicine experience deeply rooted in providing accessible and equitable oncology care for all patients. In his new role, he will be responsible for leading the commercial and clinical strategy to advance Myriad’s oncology portfolio, which currently offers germline testing, tumor profiling and companion diagnostic options, including homologous recombination deficiency testing.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MYGN:
- Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics
- Myriad Genetics signs agreement to acquire certain assets from Intermountain
- Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO
- Mesa Labs appoints Mark Capone to board of directors
- Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference